Development and validation of a HPLC method for quantification of rivastigmine in rat urine and identification of a novel metabolite in urine by LC‐MS/MS

Biomedical Chromatography - Tập 25 Số 3 - Trang 353-361 - 2011
Karthik Arumugam1, C. Mallikarjuna Rao, Ravindranath Reddy Gilibili, Ramesh Mullangi, Ganesan Subramanian, Sidhartha S. Kar, Averineni Ranjithkumar, Gopal Venkatesh Shavi, N Udupa
1Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India

Tóm tắt

AbstractA sensitive, specific and accurate HPLC method for the quantification of rivastigmine (RSM) in rat urine was developed and validated. The method involves the simple liquid–liquid extraction of RSM and pyridostigmine as an internal standard (IS) from rat urine with tertiary methyl butyl ether. The chromatographic separation of RSM and IS was achieved with 20 mm ammonium acetate buffer (pH 6.5) and acetonitrile (65:35, v/v) delivered at flow‐rate of 1 mL/min on a Kromasil KR‐100. The method was in linear range from 50 to 5000 ng/mL. The validation was done as per FDA guidelines and the results met the acceptance criteria. The method was successfully applied for the quantification of RSM in rat urine. Besides method validation, we have identified two metabolites of RSM in urine. Both the metabolites were characterized by HPLC‐PDA and LC‐MS/MS and it was found that one metabolite is novel. Copyright © 2010 John Wiley & Sons, Ltd.

Từ khóa


Tài liệu tham khảo

Bhatt J, 2007, A rapid and sensitive liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) method for the estimation of rivastigmine in human plasma, Journal of Chromatography B, 852, 15

10.1016/S1044-0305(03)00574-9

10.1016/S0140-6736(76)91936-X

10.1016/S0079-6123(08)62429-2

10.1002/bmc.304

10.1016/j.brainres.2005.08.039

10.1002/rcm.2737

10.1592/phco.20.1.1.34664

Karthik A, 2007, Ranjithkumar A and Kamat SB. Fluorimetric determination of rivastigmine in rat plasma by a reverse phase‐high performance liquid chromatographic method. Application to a pharmacokinetic study, Arzneimittelforschung, 57, 705

10.1016/S0149-2918(98)80127-6

10.1016/j.jchromb.2004.04.006

US DHHS FDA CDER.Guidance for Industry: Bioequivalence Guidance. US Department of Health and Human Services Food and Drug Administration Centre for Veterinary Medicine 2006. Available at:http://www/fda.gov/cder/guidance/index.htm

10.2165/00002512-200421070-00004

10.1002/ana.410340312

Thông tin
Thông tin xuất bản

Biomedical Chromatography

Tập 25 Số 3

353-361

Thông tin tác giả